BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · IEX Real-Time Price · USD
4.380
-0.030 (-0.68%)
At close: Apr 23, 2024, 4:00 PM
4.410
+0.030 (0.68%)
After-hours: Apr 23, 2024, 7:54 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for BCRX stock have an average target of 13.29, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 203.42% from the current stock price of 4.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BCRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +173.97% | Apr 10, 2024 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +173.97% | Jan 8, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $10 | Buy | Initiates | $10 | +128.31% | Nov 20, 2023 |
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +173.97% | Nov 6, 2023 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +128.31% | Sep 25, 2023 |
Financial Forecast
Revenue This Year
403.60M
from 331.41M
Increased by 21.78%
Revenue Next Year
485.22M
from 403.60M
Increased by 20.22%
EPS This Year
-0.62
from -1.18
EPS Next Year
-0.35
from -0.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 427.1M | 535.6M | 687.8M | 932.9M | 1.1B |
| Avg | 403.6M | 485.2M | 574.5M | 704.7M | 804.9M |
| Low | 374.4M | 390.0M | 394.0M | 505.1M | 620.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 28.9% | 32.7% | 41.7% | 62.4% | 49.4% |
| Avg | 21.8% | 20.2% | 18.4% | 22.7% | 14.2% |
| Low | 13.0% | -3.4% | -18.8% | -12.1% | -11.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.28 | -0.12 | 0.47 | 2.10 | 3.05 |
| Avg | -0.62 | -0.35 | 0.02 | 0.81 | 1.23 |
| Low | -0.82 | -0.74 | -0.86 | -0.41 | 0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 8,598.0% | 276.0% |
| Avg | - | - | - | 3,254.5% | 51.4% |
| Low | - | - | - | - | -91.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.